Gaucher pill looks promising in Phase II; Discovery Labs shakes up executive team;

 @FierceBiotech: U.S. biotech faces fierce international competition. Article | Follow @FierceBiotech

> Genzyme is reporting that a mid-stage trial of a new pill for Gaucher disease was a success. Investigators are now recruiting patients for a Phase III study. Story

> Discovery Laboratories has shaken up its executive staff with a series of new assignments. And the developer says it plans to select a permanent CEO in 2011. Report

> AVI BioPharma reports that an animal study for its experimental H1N1 drug produced promising results. Article

> Harvard Bioscience, which makes tools for drug researchers, is buying Coulbourn Instruments. Item

> Kamada will get a $20 million upfront payment from Baxter after inking a distribution deal for the newly approved Glassia, a new emphysema therapy. Report

> Soligenix has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development. Soligenix release

> Celsion says that the FDA has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation as a fast track development program. Celsion release

And Finally... Scientists have mapped the points at which vitamin D interacts with our DNA--and identified over two hundred genes that it directly influences. Release

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.